Blog

Toni Choueiri on the Flexibility of Therapies Beyond PD-1 Inhibitors

Toni Choueiri/X

Nov 9, 2024, 20:04

Toni Choueiri on the Flexibility of Therapies Beyond PD-1 Inhibitors

Toni Choueiri, Director of the Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute, shared on X:

“SUPP FIG 2 tells it all—an example we worked on taking KYN564 as an example. Subsequent therapies can be ‘many things’ and does not need to be a PD-1 inhibitor.”

Toni K. Choueiri is the Director of the Lank Center for Genitourinary (GU) Oncology at Dana-Farber Cancer Institute (DFCI), co-leader of the Kidney Cancer Program at Dana-Farber/Harvard Cancer Center, and the Jerome and Nancy Kohlberg Chair and Professor of Medicine at Harvard Medical School.

As a medical oncologist, clinical trialist, and translational researcher, he specializes in treating genitourinary cancers (prostate, bladder, testis, and kidney cancer), with a focus on kidney cancer.

cancer care cancer innovation cancer therapies cancer treatment clinical research immuno-oncology immunotherapy KYN564 Medical Advancements Oncology oncology research PD-1 inhibitor therapeutic strategies Toni Choueiri

Mark Ruffalo and Brain Cancer: How He Went Against, How He Survived, and More

Sharon Osbourne and Colon Cancer: How She Went Against, How She Survived, and More

Marcia Cross and Anal Cancer: How She Went Against, How She Survived, and More

Pancreatic Cancer: Symptoms, Causes, Types, Diagnosis & Treatment

FDA approves Methotrexate for Pediatric acute Lymphoblastic Leukemia

Special Coverage